Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
FRLN was delisted on the 16th of February, 2024.
17 hedge funds and large institutions have $33.2M invested in Freeline Therapeutics Holdings plc American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.
56% more capital invested
Capital invested by funds: $21.3M → $33.2M (+$11.9M)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
11% less funds holding
Funds holding: 19 → 17 (-2)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.01M |
| 2 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$51.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$29.8K |
| 4 |
Morgan Stanley
New York
|
+$7.05K |
| 5 |
VFA
Values First Advisors
Gray,
Tennessee
|
+$5.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$155K |
| 2 |
V
Veritable
Wilmington,
Delaware
|
-$63K |
| 3 |
Two Sigma Investments
New York
|
-$55.6K |
| 4 |
PFS
Prospera Financial Services
Dallas,
Texas
|
-$39K |
| 5 |
Two Sigma Advisers
New York
|
-$10K |
FRLN Hedge Fund Activity: Q2 2022 in Review
17 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) for Q2 2022, worth a combined $33.2M — up 56% from $21.3M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FRLN and 2 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Eventide Asset Management, adding an estimated $2.01M. The largest seller was Renaissance Technologies, cutting an estimated $155K.
- 17 institutional investors held Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) as of Q2 2022, down from 19 in Q1 2022.
- Funds reported $33.2M of Freeline Therapeutics Holdings plc American Depositary Shares stock for Q2 2022, up 56% quarter-over-quarter.
- 2 funds opened new Freeline Therapeutics Holdings plc American Depositary Shares positions in Q2 2022 and 4 closed out, a net change of -2 holders.
- The largest Freeline Therapeutics Holdings plc American Depositary Shares buyer in Q2 2022 was Eventide Asset Management, an estimated $2.01M added.
- The largest Freeline Therapeutics Holdings plc American Depositary Shares seller in Q2 2022 was Renaissance Technologies, an estimated $155K sold.
Based on aggregated 13F filings for Q2 2022.